Indeed, angiotensin-converting enzyme inhibition, a common treatment for hypertension, has anti-TGF-β and potential antifibrotic effects [5], while rho-associated coiled-coil-containing kinases (ROCK) inhibition, under development for treatment of IPF, is known to affect blood pressure [6]. This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.